Kumar Aman, Sun Ruizheng, Habib Bettina, Bencivenga-Barry Natasha A, Ivanov Ivaylo I, Tamblyn Robyn, Goodman Andrew L
Department of Microbial Pathogenesis and Microbial Sciences Institute, Yale University School of Medicine, New Haven, CT, USA.
Department of General Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Res Sq. 2024 Oct 18:rs.3.rs-5199936. doi: 10.21203/rs.3.rs-5199936/v1.
The majority of people in the U.S. manage health through at least one prescription drug. Drugs classified as non-antibiotics can adversely affect the gut microbiome and disrupt intestinal homeostasis. Here, we identified medications associated with an increased risk of GI infections across a population cohort of more than 1 million individuals monitored over 15 years. Notably, the cardiac glycoside digoxin and other drugs identified in this epidemiological study are sufficient to alter microbiome composition and risk of subsp. Typhimurium (. Tm) infection in mice. The impact of digoxin treatment on Tm infection is transmissible via the microbiome, and characterization of this interaction highlights a digoxin-responsive β-defensin that alters microbiome composition and consequent immune surveillance of the invading pathogen. Combining epidemiological and experimental approaches thus provides an opportunity to uncover drug-host-microbiome-pathogen interactions that increase infection risk in humans.
美国大多数人至少通过一种处方药来管理健康。归类为非抗生素的药物会对肠道微生物群产生不利影响,并破坏肠道内环境稳定。在此,我们在一项对100多万人进行了15年监测的人群队列中,确定了与胃肠道感染风险增加相关的药物。值得注意的是,强心苷地高辛和在这项流行病学研究中确定的其他药物足以改变小鼠的微生物群组成和鼠伤寒沙门氏菌(. Tm)感染风险。地高辛治疗对. Tm感染的影响可通过微生物群传播,这种相互作用的特征突出了一种地高辛反应性β-防御素,它会改变微生物群组成以及对入侵病原体的后续免疫监测。因此,结合流行病学和实验方法提供了一个机会,来揭示增加人类感染风险的药物-宿主-微生物群-病原体相互作用。